Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1987 1
1989 1
1991 2
1992 7
1993 3
1995 4
1996 2
1997 4
1998 3
1999 5
2000 2
2001 2
2002 3
2003 6
2004 1
2005 2
2006 1
2007 2
2008 3
2009 4
2010 1
2011 4
2012 1
2013 3
2014 1
2015 2
2016 1
2019 1
2020 1
2021 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Lucky AW, et al. J Am Acad Dermatol. 1997 Nov;37(5 Pt 1):746-54. doi: 10.1016/s0190-9622(97)70112-9. J Am Acad Dermatol. 1997. PMID: 9366821 Clinical Trial.
OBJECTIVE: Our purpose was to evaluate the efficacy of a triphasic, combination OC (ORTHO TRI-CYCLEN [Ortho-McNeil Pharmaceutical, Raritan, N.J.], norgestimate/ethinyl estradiol) compared with placebo in the treatment of moderate acne vulgaris. ...CONCLUSION: An OC contain …
OBJECTIVE: Our purpose was to evaluate the efficacy of a triphasic, combination OC (ORTHO TRI-CYCLEN [Ortho-McNeil Pharmaceutical, Raritan, …
Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.
Bifano M, Sevinsky H, Hwang C, Kandoussi H, Jiang H, Grasela D, Bertz R. Bifano M, et al. Antivir Ther. 2014;19(5):511-9. doi: 10.3851/IMP2718. Epub 2013 Dec 17. Antivir Ther. 2014. PMID: 24343001 Clinical Trial.
The primary objective of this study was to assess the effect of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate (Ortho Tri-Cyclen()). METHODS: In this open-label single-sequence study, 20 healthy female sub …
The primary objective of this study was to assess the effect of daclatasvir on the pharmacokinetics of a combined oral contraceptive contain …
Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate.
Schmitt-Hoffmann AH, Roos B, Sauer J, Schleimer M, Schoetzau A, Leese PT, Weidekamm E, Maares J. Schmitt-Hoffmann AH, et al. Clin Exp Dermatol. 2011 Apr;36 Suppl 2:4-11. doi: 10.1111/j.1365-2230.2011.04031.x. Clin Exp Dermatol. 2011. PMID: 21443598 Clinical Trial.
Similarly, the influence of ethinyl estradiol/norgestimate on systemic exposure to alitretinoin and 4-oxo-alitretinoin was not clinically relevant. Alitretinoin was well tolerated when given either alone or with ethinyl estradiol/norgestimate. CONCLUSIONS: There was …
Similarly, the influence of ethinyl estradiol/norgestimate on systemic exposure to alitretinoin and 4-oxo-alitretinoin was not clinic …
Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects.
Patel G, King A, Dutta S, Korb S, Wade JR, Foulds P, Sumeray M. Patel G, et al. J Clin Pharmacol. 2016 Jan;56(1):47-55. doi: 10.1002/jcph.581. Epub 2015 Sep 10. J Clin Pharmacol. 2016. PMID: 26120010 Clinical Trial.
Two phase 1 open-label, randomized (1:1), 2-arm drug interaction studies in healthy subjects assessed the effects of atorvastatin and ethinyl estradiol (EE)/norgestimate, both weak CYP3A inhibitors, on lomitapide pharmacokinetics with staggered (separated by 12 hour …
Two phase 1 open-label, randomized (1:1), 2-arm drug interaction studies in healthy subjects assessed the effects of atorvastatin and …
The efficacy and tolerability of norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 micrograms of ethinyl estradiol): results of an open, multicenter study of 59,701 women.
Runnebaum B, Grunwald K, Rabe T. Runnebaum B, et al. Am J Obstet Gynecol. 1992 Jun;166(6 Pt 2):1963-8. doi: 10.1016/0002-9378(92)91396-r. Am J Obstet Gynecol. 1992. PMID: 1605286 Clinical Trial.
After six cycles of use, amenorrhea occurred in 1%, spotting in 4%, and breakthrough bleeding in 3% of the participating women. Treatment with norgestimate/ethinyl estradiol had minimal effects on weight, blood pressure, pulse, lipid metabolism, and blood glucose. …
After six cycles of use, amenorrhea occurred in 1%, spotting in 4%, and breakthrough bleeding in 3% of the participating women. Treatment wi …
Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Jick S, Kaye JA, Li L, Jick H. Jick S, et al. Contraception. 2007 Jul;76(1):4-7. doi: 10.1016/j.contraception.2007.03.003. Epub 2007 May 11. Contraception. 2007. PMID: 17586129
CONTEXT: In 2006, we published a study that indicated that the new transdermal contraceptive patch containing ethinyl estradiol (EE) and the progestin norelgestromin did not increase the risk for venous thromboembolism (VTE) compared to oral contraceptive containing norgestima …
CONTEXT: In 2006, we published a study that indicated that the new transdermal contraceptive patch containing ethinyl estradiol (EE) and the …
Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol.
Gauthier A, Upmalis D, Dain MP. Gauthier A, et al. Acta Obstet Gynecol Scand Suppl. 1992;156:27-32. doi: 10.3109/00016349209156512. Acta Obstet Gynecol Scand Suppl. 1992. PMID: 1324554 Clinical Trial.
The incidence of dysmenorrhea and premenstrual syndrome was sharply reduced. Side effects reported were typical of those associated with use of low-dose oral contraceptive agents. ...The incidence of dysmenorrhea and premenstrual syndrome was sharply reduced. Those side …
The incidence of dysmenorrhea and premenstrual syndrome was sharply reduced. Side effects reported were typical of those associated w …
Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers.
Robertson P Jr, Hellriegel ET, Arora S, Nelson M. Robertson P Jr, et al. Clin Pharmacol Ther. 2002 Jan;71(1):46-56. doi: 10.1067/mcp.2002.121217. Clin Pharmacol Ther. 2002. PMID: 11823757 Clinical Trial.
METHODS: This was a placebo-controlled, single-blind, single-period study in 41 female subjects who were receiving long-term treatment with an oral contraceptive that contained ethinyl estradiol (0.035 mg) and norgestimate (0.180-0.250 mg). Pharmacokinetic profiles for eth …
METHODS: This was a placebo-controlled, single-blind, single-period study in 41 female subjects who were receiving long-term treatment with …
Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent.
Andolsek KM. Andolsek KM. Acta Obstet Gynecol Scand Suppl. 1992;156:22-6. doi: 10.3109/00016349209156511. Acta Obstet Gynecol Scand Suppl. 1992. PMID: 1324553 Clinical Trial.
Effective cycle control was demonstrated based on two multicenter, 2-year studies of the triphasic oral contraceptive (OC) agent containing the new progestin norgestimate. The estrogen in this OC is ethinyl estradiol. These open-label Phase III studies were conducted in th …
Effective cycle control was demonstrated based on two multicenter, 2-year studies of the triphasic oral contraceptive (OC) agent containing …
Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.
Hampton RM, Short M, Bieber E, Bouchard C, Ayotte N, Shangold G, Fisher AC, Creasy GW. Hampton RM, et al. Contraception. 2001 Jun;63(6):289-95. doi: 10.1016/s0010-7824(01)00214-1. Contraception. 2001. PMID: 11672549 Clinical Trial.
This multicenter study compared the contraceptive efficacy, cycle control, and safety of a new triphasic norgestimate (180/215/250 microg)/ethinyl estradiol 25 microg regimen (Ortho Tri-Cyclen Lo) (n = 1,723) with that of norethindrone acetate 1 mg/ethinyl estradiol 20 mic …
This multicenter study compared the contraceptive efficacy, cycle control, and safety of a new triphasic norgestimate (180/215/250 mi …
72 results